Gary D. Lopaschuk
- PhD. (Pharmacology and Toxicology, University of British Columbia) 1983
- MSc. (Pharmacology and Toxicology, University of British Columbia) 1980
- BSc. (Pharmaceutical Sciences, University of British Columbia) 1978
Scientific Director, Mazankowski Alberta Heart Institute Distinguished University Professor, Pediatrics Distinguished University Professor, Pharmacology AHFMR Scientist, University of Alberta, Edmonton, Canada
His research focuses on the regulation of fatty acid oxidation and mechanism by which high rates of fatty acid oxidation contribute to ischemic injury, and how alterations in fatty acid metabolism contribute to cardiovascular disease in the diabetic. At a molecular level he has characterized a number of key enzymes important in the regulation of cardiac fatty acid oxidation. He is also investigating how metabolic strategies can be used to protect the heart during and following ischemia.
He is a Heritage Medical Scientist, and serves on a number of journal editorial boards, including Circulation Research, J Molecular and Cellular Cardiology, the Canadian Journal of Physiology and Pharmacology, Heart and Metabolism, and Cardiovascular Drugs and Therapy. He has published over 180 original research articles, as well as over 60 reviews and book chapters. He is also the President and CEO of a biotechnology company (Metabolic Modulators Research Ltd.), that is developing novel drugs to treat heart disease that optimize energy metabolism in the heart.
423 Heritage Medical Research Center, University of Alberta, Edmonton, Canada T6G 2S2
tel: (780) 492-2170
fax: (780) 492-9753